Childhood Scleroderma and Its Peculiarities

Cutis

Volumn 58, Issue 2, 1996, Pages 141-152

  Blaszczyk, Maria ^a   Janniger, Camila Krysicka ^a   Jablonska, Stefania ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE MALFORMATION; CHILDHOOD DISEASE; CLINICAL FEATURE; FIBROSIS; HEMIFACIAL ATROPHY; HUMAN; MORPHEA; SKIN BIOPSY; SYSTEMIC SCLEROSIS;

AGE OF ONSET; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; MALE; PROGNOSIS; RISK FACTORS; SCLERODERMA, SYSTEMIC; SEX DISTRIBUTION;

EID: 0029815606     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (103)

1. Jablonska S: Scleroderma and Pseudoscleroderma. Warsaw, Polish Med Publ, distributor Dowden, Hutehinson Press, Strousburg, Penn, 1975.
2. Jablonska S, Rodnan GP: Localized forms of scleroderma. Clin Rheumatol 5: 215-241, 1979.
3. Krafchik BR Localized cutaneous scleroderraa. Semin Dermatol 1: 56-72, 1992.
4. Ansell BM, Falcini F, Wood P: Scleroderma in childhood, Clin Dermatol 12: 299-307, 1994.
5. Jablonska S, Bubnow B, Szczepanski A: Morphea: is it a separate entity or a variety of scleroderma? Dermatologica 125: 140-154, 1962.
6. Soma Y, Tamaki T, Kikuchi K, et al: Coexistence of morphea and systemic sclerosis. Dermatology 186: 103-105, 1993.
7. Falanga V, Medsger TA, Reichlin M, et al: Linear scleroderma. Clinical spectrum, prognosis and laboratory abnormalities. Ann Intern Med 104: 849-857, 1986.
8. Jablonska S, Chorzelski TP, Blaszczyk M, et al: Clinical relevance of immunologic findings in scleroderma. Clin Dermatol 10: 407-421, 1993.
9. Jablonska S: Connection between scleroderma and the autonomic nervous system. Acta Neuroveg (Wien) 24: 50-60, 1963.
10. Wettke-Schafer R, Kantner G: X-linked dominant inherited diseases with lethality in hemizygous males. Hum Genet 64: 1-23, 1983.
11. Happle R: Lyonization and the lines of Blaschko. Hum Genet 70: 200-206, 1985.
12. Happle R: Mosaicism in human skin. Understanding the patterns and mechanisms. Arch Dermatol 129: 1460-1470, 1993.
13. Bolognia JL, Orlow SJ, Click SA: Lines of Blaschko. J Am Acad Dermatol 31: 157-190, 1994.
14. Blaschko A: Die Nervenverteilung in der Haut in ihrer Beziehung zu den Erkrankungen der Haut Verhandlungen der Deutschen Dermatologischen Gesellschaft VII Congress Bresslau, 1901, Vienna.
15. Cassirer R: Die Vasomotorisch-Trophischen Neurosen. Berlin, Karger, 1912.
16. Marburg O: Die Hemiatrophia facialis progressiva. Vienna, A Holder, 1912.
17. Archambault LS, Fromm NK Progressive facial hemiatrophy: report of three cases. Arch Neurol Psychiatry 27: 529-584, 1932.
18. Salomons B: Linear scleroderma with epilepsy and facial hemiatrophy. Br J Dermatol 67: 412, 1955.
19. Stava Z: The problem of interrelation between diffuse generalized scleroderma, acrosclerosis, Raynaud's phenomenon, and Raynaud's disease. Dermatologica 118: 1-11, 1959.
20. Hermann WP: Hemiatrophia faciei mit Sklerodermie und hirnorganischen Anfallen. Z Haut Geschlechtskr 107: 332-333, 1960.
21. Terstegge K, Henkes H, Kunath B: Zerebrale Manifestation der progressiven fazialen Hemiatrophie (Romberg-Erkrankung). Radiologe 33: 585-595, 1993.
22. Wartenberg R: Progressive facial hemiatrophy. Arch Neurol Psychiatry 54: 75-96, 1945.
23. Connolly MG, Winkelman RK: Coexistence of liehen sclerosus, morphea, and liehen planus. Report of four cases and review of the literature. J Am Acad Dermatol 12: 844-851, 1985.
24. Uitto J, Sauta Cruz DJ, Bauer EA, et al: Morphea and lichen sclerosus et atrophicus. J Am Acad Dermatol 3: 271-279, 1980.
25. Natarajan S, Green ST: Generalized morphea, lichen sclerosus et atrophicus and primary biliary cirrhosis. Clin Exp Dermatol 11: 304-308, 1986.
26. Shono S, Imura M, Ota M, et al: Lichen sclerosus et atrophicus, morphea, and coexistence of both diseases. Arch Dermatol 127: 1352-1356, 1991.
27. Lampert A, Fortier-Beaulien M, Thomine E, et al: Association sur un membre d'un lichen sclereux et d'une sclerodermie monomelique. Ann Dermatol Venereol 122: 102-104, 1995.
28. Tremaine R, Adam JE, Orizaga M: Morphea coexisting with lichen sclerosus et atrophicus. Int J Dermatol 29: 486-489, 1990.
29. Izumi T, Tajima S: A case of linear type of lichen sclerosus et atrophicus? J Dermatol 22: 279-282, 1995.
30. Godeau G, Frances C, Hornebeck W, et al: Isolation and patrial characterization of an elastase type protease in human vulvar elastic tissue destruction of patients with lichen sclerosus et atrophicus. J Invest Dermatol 78: 270, 1982.
31. Mihara Y, Mihara M, Hagari Y, et al: Lichen sclerosus et atrophicus. A histological, immunohistochemical and electron microscopic study. Arch Dermatol Res 286: 434-442, 1994.
32. Rahbari H: Histochemical differentiation of localized morpheascleroderma and liehen sclerosus et atrophicus. J Cutaneous Pathol 16: 342-347, 1989.
33. Shulman HM, Sale GE, Lerner KG, et al: Chronic cutaneous graft-versus-host disease in man. Am J Pathol 91: 545-570, 1978.
34. Sullivan KM: Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 4 (Suppl): 42-93, 1986.
35. Herzberg JJ, Heyer-Rohn J, Unna PG, et al: Sclerolichen Gougerot liehen ruber planus. liehen sclerosus et atrophicus. Sclerodermia en plaques und vitiligo: gleichzeitiges Verkommen bei einem Kranken mit Lungentuberkulose. Arch Klin Exp Dermatol 216: 246-259, 1963.
36. Helm KF, Gibson LE, Muller SA: liehen sclerosus et atrophicus in children and young adults. Pediatr Dermatol 8: 97-101, 1991.
37. Aberer E, Stanek G: Histological evidence for spirochetal origin of morphea and lichen sclerosus et atrophicans. Am J Dermatopathol 9: 374-379, 1987.
38. Petterson JA, Ackerman AB: Lichen sclerosus et atrophicus is not related to morphea. A clinical and histologic study of 24 patients in whom both conditions were reputed to be present simultaneously. Am J Dermatopathol 6: 323-335, 1984.
39. Stefanato CM, Gorkiewicz-Petkow A, Jarzabek-Chorzelska M, et al: Morphea with high titer of fibronection antibodies. Int J Dermatol 31: 190-192, 1992.
40. Prendiville JS: Resolution of solitary morphea profunda associated with generalized vitiligo. Pediatr Dermatol 11: 362-363, 1994.
41. Kobayashi KA, Lui H, Prendiville JS: Solitary morphea profunda in a 5-year-old girl: case report and review of the literature. Pediatr Dermatol 8: 292-295, 1991.
42. Whittaker SJ, Smith NP, Jones RR: Solitary morphea profunda. Br J Dermatol 120: 431440, 1989.
43. Su DWP, Person JR Morphea profunda. A new concept and a histopathologic study of 23 cases. Am J Dermatopathol 3: 251-260, 1981.
44. Barrier H, Litoux P, Bureau B, et al: La morphée generalisée. Bull Soc Fr Dermatol Syphiligr 81: 336-341, 1974.
45. Jablonska S, Lovell CHR Localized scleroderma. In, Systemic Sclerosis: Scleroderma (Jayson MIV, Black CM, eds), pp 303-318. New York, John Wiley and Sons, 1988.
46. Diaz-Perez JL, Connoly SM, Winkelmann KK: Disabling pansclerotic morphea of children. Arch Dermatol 116: 169-173, 1980.
47. Kencka D, Blaszczyk M, Jablonska S: Atrophoderma Pasini-Pierini is a primary atrophie abortive morphea. Dermatology 190: 203-206, 1995.
48. Jablonska S, Szczepanski A: Atrophoderma Pasini-Pierini: is it an entity? Dermatologica 125: 226-242, 1962.
49. Buchner SA, Rufli T: Atrophoderma of Pasini and Pierini. J Am Acad Dermatol 30: 441446, 1994.
50. Di Silvero A, Serri F: Generalized bullous and haemorrhagic lichen sclerosus et atrophicus. Br J Dermatol 93: 215-217, 1975.
51. Kobayasi T, Willebeerg A, Serup J, et al: Generalized morphea with blisters. Acta Derm Venereal (Stockh) 70: 454-456, 1990.
52. Neucks SH, Moore TL, Lichtenstein JR, et al: Localized scleroderma and idiopathic thrombocytopenia, J Rheumatol 7: 741-744, 1980.
53. Leibovici V, Zlotogorski A, Kanner A, et al: Generalized morphea and idiopathic thrombocytopenia. J Am Acad Dermatol 18: 1194-1196, 1988.
54. Birdi N, Laxer RM, Thorner P, et al: Localized scleroderma progressing to systemic disease. Case report and review of the literature. Arthritis Rheum 36: 410-415, 1993.
55. Dehen L, Roujeau JC, Cosnes A, et al: Internal involvement in localized scleroderma. Medicine 73: 241-245, 1994.
56. Luderschmidt CH, Konig G, Leisner B, et al: Zirkumskripte Sklerodermie: Interne Manifestationen und signifikante Korrelation zu HLA-DR 1 und DR 5. Hautarzt 36: 516-521, 1985.
57. Weihrauch TR, Korting GW: Manometric assessment of oesophagel involvement in progressive systemic sclerosis, morphea and Raynaud's disease. Br J Dermatol 107: 325-332, 1982.
58. Hamel-Roy J, Devroede G, Arhan P, et al: Comparative esophageal and anorectal mobility in scleroderma. Gastroenterology 88: 1-7, 1985.
59. Takehara K, Moroi Y, Nakabayashi Y, et al. Antinuclear antibodies in localized scleroderma. Arthritis Rheum 26: 612-616, 1983.
60. Falanga V, Medsger TA, Reichlin M: Antinuclear and anti-single stranded DNA antibodies in morphea and generalized morphea. Arch Dermatol 123: 350-353, 1987.
61. Takehara K, Kikuchi K, Soma Y, et al: Anti-single-stranded DNA antibody and muscle involvement in localized scleroderma. Arch Dermatol 126: 1368-1369, 1990.
62. Sato S, Ihn H, Soma Y, et al: Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum 36: 1137-1141, 1993.
63. Sato S, Fujimoto M, Ihn H, et al: Antigen specificity of antihistone antibodies in localized scleroderma. Arch Dermatol 130: 1273-1277, 1994.
64. Fujimoto M, Sato S, Ihn H, et al: Antibodies to the heat-shock protein hsp 73 in localized scleroderma. Arch Dermatol Res 287: 581-585, 1995.
65. Harrington I, Dunsmore IR An investigation into the incidence of autoimmune disorders in patients with localized morphea. Br J Dermatol 120: 645-648, 1989.
66. Scarola JA, Shulman LE: Serologic abnormalities and their significance in localized scleroderma. Arthritis Rheum 18: 526-527, 1975.
67. Weidner F, Braun-Falco O: Gleichzeitiges Vorkommen von Symptomen der circumscripten und progressiven Sklerodermie. Hautarzt 19: 345-350, 1968.
68. Temime P, Privat Y, Valletta P: Sclerodermie en plaques et en gouttes avec hypertension arterielle pulmonaire. Bull Soc Fr Dermatol Syphiligr 77: 216-217, 1970.
69. Ikai K, Tagami H, Imamura S, et al: Morphea-like cutaneous changes in a patient with systemic scleroderma. Dermatologica 158: 438-442, 1979.
70. Ryckmanns F, Konz B: Disseminierte zirkumskripte Sklerodermie und diffuse Sklerodermie vom Typ der Akrosklerodermie. Hautarzt 31: 86-90, 1980.
71. Mizutani H, Tanaka H, Okada H, et al: Palindromic morphea: multiple recurrence of morphea lesions in a case of systemic sclerosis. J Dermatol 19: 298-301, 1992.
72. Tufanelli DL, Marmalrat WL, Dorsey CS: Linear scleroderma with hemiatrophy: report of three cases associated with collagen-vascular disease. Dermatologica 132: 51-58, 1966.
73. Jablonska S: Progress in new clinical aspects of scleroderma. Eur J Dermatol 2: 143-146, 1992.
74. Jablonska S, Rudnicka L, Majewski S: Sklerodermie heute. In, Dermatologie Heutiger Stand (Tebbe B, Goerdt S, Orfanos CE, eds), pp 149-151. Stuttgart, Georg Thieme Verlag, 1995.
75. Needelman BW, Wigley FM, Atair RW: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor a and Interferon γ levels in sera from patients with scleroderma. Arthritis Rheum 35: 67-72, 1992.
76. Rudnicka L, Majewski S, Blaszczyk M, et al: Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma). Arthritis Rheum 35: 771-774, 1992.
77. Majewski S, Hunzelmann N, Johnson JP, et al: Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patiente with systemic scleroderma. J Invest Dermatol 97: 667-671, 1991.
78. Ohta A, Uitto J: Procollagen gene expression by scleroderma fibroblasts in culture. Arthritis Rheum 30: 404-408, 1987.
79. Gay S, Trabandt A, Moreland W, et at Growth factors, extracellular matrix and oncogenes in scleroderma. Arthritis Rheum 35: 304-310, 1992.
80. Hatamochi A, Ono M, Arakawa M, et al: Analysis of collagen gene expression by cultured fibroblasts in morphea. Br J Dermatol 126: 216-221, 1992.
81. Rudnicka L, Varga J, Iozzo R, et al: Elevated expression of type VII collagen in patients with systeme sclerosis. J Clin Invest 93: 1709-1717, 1994.
82. Falanga V, Tiegs SL, Alstadt SP, et al: TGFß selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis. J Invest Dermatol 89: 100-104, 1987.
83. Higley H, Persichitte K, Chu I, et al: Immunocytochemical localization and serologic detection of transforming growth factor ß1. Arthritis Rheum 37: 278-288, 1994.
84. Ihn H, Fujimoto M, Sato S, et al: Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma. J Am Acad Dermatol 31: 591-595, 1994.
85. Ihn H, Sato S, Fujimoto M, et al: Demonstration of interleukin-2, interleukin4, and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 287: 193-197, 1995.
86. Uziel Y, Krafchik BR, Feldman B, et al: Serum levels of soluble interleukin-2 receptor. A marker of disease activity in localized scleroderma. Arthritis Rheum 37: 889-901, 1994.
87. Majewski S, Wojas-Pelc A, Malejczyk M, et al: Increased serum levels of soluble TNFα receptor type I - a novel marker of severity of systemic sclerosis. International Workshop on Systemic Sclerosis, Roma, 1995, Book of Abstracts, p 30.
88. Izumi T, Tajima S, Nishikawa T: Stimulated expression of decorin and the decorin gene in fibroblasts cultured from patients with localized scleroderma. Arch Dermatol Res 287: 417-420, 1995.
89. Zachariae H, Halkier-Sorensen L, Heikendorff L: Serum aminoterminal propeptide of type III procollagen in progressive systemic sclerosis and localized scleroderma. Acta Derm Venereal (Stockh) 69: 66-70, 1989.
90. Kikuchi K, Sato S, Kadono T, et al: Serum concentration of procollagen type I carboxyterminal propeptide in localized scleroderma. Arch Dermatol 130: 1269-1272, 1994.
91. Krieg T, Langer I, Gertmeier H, et al: Type III collagen amino propeptide levels in serum of patients with progressive systemic scleroderma. J Invest Dermatol 87: 788-791, 1986.
92. Majewski S, Skiendzielewska A, Makiela B, et al: Serum levels of type III collagen aminopropeptide in serum of patients with systemic scleroderma. Arch Dermatol Res 279: 484-486, 1987.
93. Jablonska S, Groniowski J, Krieg T, et al: Congenital fascial dystrophy: a noninflammatory disease of fascia - the stiff skin syndrome. Pediatr Dermatol 2: 87-97, 1984.
94. Jablonska S, Schubert S, Kikuchi J: Congenital fascial dystrophy: stiff skin syndrome - a human counterpart of the tight-skin mouse. J Am Acad Dermatol 25: 943-950, 1989.
95. Jablonska S, Blaszczyk M: Sclerodermalike disease. Clin Dermatol 12: 437-448, 1994.
96. Jablonska S, Blaszczyk M: Differential diagnosis of sclerodermalike disorders. In, Systemic Sclerosis (Clements PJ, Furst DE, eds), pp 99-120. Baltimore, Williams and Wilkins, 1995.
97. Jablonska S, Blaszczyk M, Rudnicka L, et al: Sclerodermalike fibrosing skin conditions and unusual forms of scleroderma. Life Chem Reps 14: 125-136, 1996.
98. Fleischmajer R, Perlish JS, Reeves IRT: Cellular infiltrates in scleroderma skin. Arthritis Rheum 20: 975-984, 1977.
99. 3: evaluation of skin involvement using non-invasive techniques. Acta Derm Venereol (Stockh) 73: 449-451, 1993.
100. Hulshof MM, Pavel S, Breedveld PC, et al: Oral calcitriol as a new therapeutic modality for generalized morphea. Arch Dermatol 130: 1290-1293, 1994.
101. Kerscher M, Volkenandt M, Meurer M, et al: Treatment of localized scleroderma with PUVA bath photochemotherapy. Lancet 343: 1233, 1994.
102. Hoffmann K, Gerbaulet U, el Gammal S, et al: 20-Mhz B-mode ultrasound in monitoring the course of localized scleroderma (morphea). Acta Derm Venereal (Stockh) 164 (Suppl): 3-16, 1991.
103. Klyscz T, Hahn M, Junger M: Laser-Doppler-Flux-Messungen zur Therapie-kontrolle bei zirkumskripter Sklerodermie. Hautarzt 46: 421-424, 1995.